Advanced glycation end products modulate the maturation and function of peripheral blood dendritic cells

Diabetes

Volumn 53, Issue 6, 2004, Pages 1452-1458

  Price, Claire L ^a   Sharp, Patrick S ^b   North, Margaret E ^a   Rainbow, Sandra J ^b   Knight, Stella C ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; B7 ANTIGEN; CD83 ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN PROCESSING; VASCULAR DISEASE;

ADRENOCORTICOTROPIC HORMONE; ANTIGENS, CD; BLOOD CELLS; CELL COUNT; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE GLYCOPROTEINS; MONOCYTES; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; UP-REGULATION;

EID: 2542524769     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.6.1452     Document Type: Article

References (33)

1. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116, 1999
2. Westwood ME, Argirov OK, Abordo EA, Thornalley PJ: Methylglyoxal-modified arginine residues: a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. Biochim Biophys Acta 1356:84-94, 1997
3. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF: Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52:163-167, 2003
4. Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Intern Med 251:87-101, 2002
5. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 44:129-146, 2001
6. Sharp PS, Rainbow S, Mukherjee S: Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 20:575-579, 2003
7. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H: The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 49:1030-1035, 2000
8. Knight SC, Stagg AJ: Antigen-presenting cell types. Curr Opin Immunol 5:374-382, 1993
9. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392:245-252, 1998
10. Iking-Konert C, Wagner C, Denefleh B, Hug F, Schneider M, Andrassy K, Hansch GM: Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease. Clin Exp Immunol 130:501-508, 2002
11. Mahanonda R, Sa-Ard-Iam N, Yongvanitchit K, Wisetchang M, Ishikawa I, Nagasawa T, Walsh DS, Pichyangkul S: Upregulation of co-stimulatory molecule expression and dendritic cell marker (CD83) on B cells in periodontal disease. J Periodontal Res 37:177-183, 2002
12. Scholler N, Hayden-Ledbetter M, Hellstrom KE, Hellstrom I, Ledbetter JA: CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J Immunol 166:3865-3872, 2001
13. Kruse M, Rosorius O, Kratzer F, Bevec D, Kuhnt C, Steinkasserer A, Schuler G, Hauber J: Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med 191:1581-1590, 2000
14. Fujimoto Y, Tu L, Miller AS, Bock C, Fujimoto M, Doyle C, Steeber DA, Tedder TF: CD83 expression influences CD4+ T cell development in the thymus. Cell 108:755-767, 2002
15. Stern DM, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1:1-15, 2002
16. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ: Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J 364:1-14, 2002
17. Ahmed N, Thornalley PJ: Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 364:15-24, 2002
18. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126, 1999
19. Peng R, Li Y, Brezner K, Litherland S, Clare-Salzler MJ: Abnormal peripheral blood dendritic cell populations in type 1 diabetes. Ann N Y Acad Sci 1005:222-225, 2003
20. Eibl N, Spatz M, Fischer GF, Mayr WR, Samstag A, Wolf HM, Schernthaner G, Eibl MM: Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 103:249-259, 2002
21. Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, Mayr WR, Schernthaner G, Eibl MM: Impaired primary immune response in type-1 diabetes: functional impairment at the level of APCs and T-cells. Cell Immunol 221:15-26, 2003
22. Lechmann M, Krooshoop DJ, Dudziak D, Kremmer E, Kuhnt C, Figdor CG, Schuler G, Steinkasserer A: The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 194:1813-1821, 2001
23. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118, 1994
24. Gu K, Cowie CC, Harris MI: Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21:1138-1145, 1998
25. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM: Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41:1071-1077, 2003
26. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 49:485-491, 2000
27. Bobryshev YV, Lord RS: Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 37:799-810, 1998
28. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link? Lancet 350:430-436, 1997
29. Libby P, Egan D, Skarlatos S: Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 96:4095-4103, 1997
30. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-955, 2001
31. Nicoloff G, Baydanoff S, Petrova C, Christova P: Antibodies to advanced glycation end products in children with diabetes mellitus. Vascul Pharmacol 39:39-45, 2002
32. Zacher T, Knerr I, Rascher W, Kalden JR, Wassmuth R: Characterization of monocyte-derived dendritic cells in recent-onset diabetes mellitus type 1. Clin Immunol 105:17-24, 2002
33. Ahmed N, Thomalley PJ: Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 31:1417-1422, 2003